m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00262)
Target Name Far upstream element-binding protein 1 (FUBP1)
Synonyms
FBP; FUSE-binding protein 1; DNA helicase V; hDH V
    Click to Show/Hide
Gene Name FUBP1
Chromosomal Location 1p31.1
Function
Regulates MYC expression by binding to a single-stranded far-upstream element (FUSE) upstream of the MYC promoter. May act both as activator and repressor of transcription.
    Click to Show/Hide
Gene ID 8880
Uniprot ID
FUBP1_HUMAN
HGNC ID
HGNC:4004
Ensembl Gene ID
ENSG00000162613
KEGG ID
hsa:8880
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
FUBP1 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line DKO-1 cell line Homo sapiens
Treatment: METTL3 knockdown DKO-1 cell
Control: DKO-1 cell
 GSE182382
Regulation
logFC: 6.14E-01
p-value: 4.72E-03
More Results Click to View More RNA-seq Results
Representative RIP-seq result supporting the interaction between FUBP1 and the regulator
Cell Line MDA-MB-231 Homo sapiens
Regulation logFC: 1.31E+00 GSE60213
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary LCAT3 upregulation is attributable to N6-methyladenosine (m6A) modification mediated by methyltransferase like 3 (METTL3), leading to LCAT3 stabilization. LCAT3 as a novel oncogenic lncRNA in the lung, and validated the LCAT3-Far upstream element-binding protein 1 (FUBP1)-MYC axis as a potential therapeutic target for lung adenocarcinomas.
Target Regulation Up regulation
Responsed Disease Lung adenocarcinoma ICD-11: 2C25.0
 Disease Info 
In-vitro Model A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
Calu-1 Lung squamous cell carcinoma Homo sapiens CVCL_0608
HEK293T Normal Homo sapiens CVCL_0063
HOP-62 Lung adenocarcinoma Homo sapiens CVCL_1285
In-vivo Model For the in vivo tumorigenicity assay, female BALB/c nude mice (ages 4-5 weeks) were randomly divided into two groups (n = 6/group). Calu1 cells (4 × 106) that had been stably transfected with sh-LCAT3 or scramble were implanted subcutaneously into the nude mice. Tumor growth was measured after one week, and tumor volumes were calculated with the following formula: Volume (cm3) = (length × width2)/2. After four weeks, the mice were euthanized, and the tumors were collected and weighed. For the in vivo tumor invasion assay, 1.2 × 106 scramble or shLCAT3 cells were injected intravenously into the tail vein of nude mice (n = 6/group). 1.5 mg luciferin (Gold Biotech, St Louis, MO, USA) was administered once a week for 4 weeks, to monitor metastases using an IVIS@ Lumina II system (Caliper Life Sciences, Hopkinton, MA, USA).
Lung cancer [ICD-11: 2C25]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary LCAT3 upregulation is attributable to N6-methyladenosine (m6A) modification mediated by methyltransferase like 3 (METTL3), leading to LCAT3 stabilization. LCAT3 as a novel oncogenic lncRNA in the lung, and validated the LCAT3-Far upstream element-binding protein 1 (FUBP1)-MYC axis as a potential therapeutic target for lung adenocarcinomas.
Responsed Disease Lung adenocarcinoma [ICD-11: 2C25.0]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
In-vitro Model A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
Calu-1 Lung squamous cell carcinoma Homo sapiens CVCL_0608
HEK293T Normal Homo sapiens CVCL_0063
HOP-62 Lung adenocarcinoma Homo sapiens CVCL_1285
In-vivo Model For the in vivo tumorigenicity assay, female BALB/c nude mice (ages 4-5 weeks) were randomly divided into two groups (n = 6/group). Calu1 cells (4 × 106) that had been stably transfected with sh-LCAT3 or scramble were implanted subcutaneously into the nude mice. Tumor growth was measured after one week, and tumor volumes were calculated with the following formula: Volume (cm3) = (length × width2)/2. After four weeks, the mice were euthanized, and the tumors were collected and weighed. For the in vivo tumor invasion assay, 1.2 × 106 scramble or shLCAT3 cells were injected intravenously into the tail vein of nude mice (n = 6/group). 1.5 mg luciferin (Gold Biotech, St Louis, MO, USA) was administered once a week for 4 weeks, to monitor metastases using an IVIS@ Lumina II system (Caliper Life Sciences, Hopkinton, MA, USA).
References
Ref 1 LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC. J Hematol Oncol. 2021 Jul 17;14(1):112. doi: 10.1186/s13045-021-01123-0.